Browsing by Author "Cagliyan, GA"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
    Serin, I; Dogu, MH; Ekinci, O; Cagliyan, GA; Bastürk, A; Aras, MR; Demircioglu, S; Turgut, B; Merter, M; Hacioglu, SK; Bagci, M; Albayrak, M; Korkmaz, S; Erkurt, MA; Dal, MS; Dursun, FE; Tombak, A; Aydogdu, I; Ulas, T; Altuntas, F
    Introduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: >= 35%) by imaging and control of hematocrit levels (<= 45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman's rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman's rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher's exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.
  • No Thumbnail Available
    Item
    The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
    Akpinar, S; Dogu, MH; Celik, S; Ekinci, O; Hindilerden, IY; Dal, MS; Davulcu, EA; Tekinalp, A; Hindilerden, F; Ozcan, BG; Hacibekiroglu, T; Erkurt, MA; Bagci, M; Namdaroglu, S; Korkmaz, G; Bilgir, O; Cagliyan, GA; Ozturk, HBA; Serin, I; Tiryaki, TO; Ozatli, D; Korkmaz, S; Ulas, T; Eser, B; Turgut, B; Altuntas, F
    We evaluated the safety and efficacy of single-agent ibrutinib in 200 patients presenting with relapsed/refractory CLL in real-world settings. With an estimated median OS of 52 months, 146 patients (75%) achieved at least PR; 16 (8.7%) patients discontinued ibrutinib due to adverse events. The results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the par ticipating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+ /p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were >= grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atr ial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare dur ing the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. (C) 2021 Elsevier Inc. All rights reserved.
  • No Thumbnail Available
    Item
    Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience
    Gemici, A; Aydogdu, I; Terzi, H; Sencan, M; Aslan, A; Kaya, AH; Dal, MS; Akay, MO; Dogu, MH; Ayyildiz, O; Sahin, F; Cagliyan, GA; Yilmaz, M; Gokgoz, Z; Bilen, Y; Demir, C; Sevindik, OG; Korkmaz, S; Eser, B; Altuntas, F
    Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.
  • No Thumbnail Available
    Item
    The outcome of eltrombopag therapy in immune thrombocytopenia: a multicenter study from Turkey
    Pamuk, GE; Maden, M; Sari, HI; Erkurt, MA; Keskinkilic, M; Cagliyan, GA; Kaya, AH; Sincan, G; Turak, ET; Ilkkilic, K; Kuku, I; Aydogdu, I; Tekgunduz, E; Sencan, M; Albayrak, M; Berber, I; Karakus, V; Gemici, AI; Korkmaz, S; Keskin, A; Eser, B; Altuntas, F
  • No Thumbnail Available
    Item
    International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report
    Ozatli, D; Giden, AO; Erkurt, MA; Korkmaz, S; Basci, S; Ulas, T; Turgut, B; Yigenoglu, TN; Hacibekiroglu, T; Basturk, A; Dal, MS; Namdaroglu, S; Hindilerden, F; Hacioglu, SK; Cagliyan, GA; Ilhan, G; Kacmaz, M; Uysal, A; Merter, M; Ekinci, O; Dursun, FE; Tekinalp, A; Demircioglu, S; Sincan, G; Acik, DY; Akdeniz, A; Ucar, MA; Yeral, M; Ciftciler, R; Teke, HU; Umit, EG; Karakus, A; Bilen, Y; Yokus, O; Albayrak, M; Demir, C; Okan, V; Serefhanoglu, S; Karti, S; Ozkurt, ZN; Eser, B; Aydogdu, I; Kuku, I; Cagirgan, S; Sonmez, M; Ozet, G; Altuntas, F
    Therapeutic apheresis is an extracorporeal treatment that selectively removes abnormal cells or harmful sub-stances in the blood that are associated with or cause certain diseases. During the last decades the application of therapeutic apheresis has expanded to a broad spectrum of hematological and non-hematological diseases due to various studies on the clinical efficacy of this procedure. In this context there are more than 30 centers per-forming therapeutic apheresis and registered in the apheresis database in Turkey. Herein, we, The Turkish Apheresis Registry, aimed to analyze some key articles published so far from Turkey regarding the use of apheresis for various indications.